MS4A1 and lymphoma: It has been shown that CD19 and CD20 expression can be heterogeneous in lymphoma subpopulations (16–18) and that CD19 expression is preserved in small CD20-negative tumor subpopulations or after CD20-targeted immunotherapy (17, 19).